Singapore markets closed

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7100+0.0100 (+0.59%)
At close: 04:00PM EDT
1.6200 -0.09 (-5.26%)
Pre-market: 08:01AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7000
Open1.6500
Bid1.7000 x 400
Ask1.7300 x 400
Day's range1.6301 - 1.7600
52-week range0.7700 - 14.0000
Volume142,791
Avg. volume6,515,841
Market cap6.934M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

    GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial’s intellectual property protection and covers the combination of the Company’s proprietary g

  • GlobeNewswire

    Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

    Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trialGLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high c

  • GlobeNewswire

    Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

    Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a